<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02189811</url>
  </required_header>
  <id_info>
    <org_study_id>PEGS</org_study_id>
    <nct_id>NCT02189811</nct_id>
  </id_info>
  <brief_title>Polio End-game Strategies - Poliovirus Type 2 Challenge Study</brief_title>
  <official_title>Polio End-game Strategies - Poliovirus Type 2 Challenge Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aga Khan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Aga Khan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Poliomyelitis eradication has entered its last phase with only three remaining endemic&#xD;
      countries, of which Pakistan is one. There hasn't been a case of wild type poliovirus 2 since&#xD;
      1999, and no case of wild type poliovirus 3 since November 2012. However, paralytic polio&#xD;
      resulting from circulating strains of Sabin poliovirus type 2 have become a challenge, and&#xD;
      reported from several areas with low population immunity to polio, including in Pakistan.&#xD;
      This study will provide data to National Immunization Authorities in order to make strategic&#xD;
      decisions about their polio vaccination schedules in anticipation of the global tOPV to bOPV&#xD;
      switch and will provide data on the proposed responses to type 2 poliovirus outbreaks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The &quot;Polio Endgame Strategy&quot; consists of set of tasks and activities that will be implemented&#xD;
      in the next five years. It includes gradual withdrawal of the widely used oral poliomyelitis&#xD;
      vaccine (OPV) containing live poliovirus, and will eventually lead to complete eradication&#xD;
      and containment of all wild, vaccine-related (VDPV) and Sabin polioviruses. The withdrawal of&#xD;
      the type 2 components of trivalent OPV (tOPV) is the key component in the elimination of&#xD;
      cVDPVs. This entails strengthening of the immunization system by introducing at least one&#xD;
      dose of affordable IPV into the routine immunization schedule globally and then replacing the&#xD;
      trivalent OPV with bivalent OPV in all OPV-using countries - setting the stage for eventually&#xD;
      ending bOPV use in 2019-2020. Most of the developing countries have an OPV schedule however&#xD;
      many developed and European countries follow the IPV only schedule. The current&#xD;
      recommendations for polio eradication and endgame is IPV vaccine to be administered together&#xD;
      with third OPV dose, which in most countries occurs at 14 weeks of age.&#xD;
&#xD;
      This study will assess the protection to type 2 poliovirus achieved after completion of the&#xD;
      recommended schedule with bOPV and IPV; it will compare immunogenicity of bOPV + IPV schedule&#xD;
      with tOPV only schedule; and will quantify the cross-reactivity of bOPV on inducing type 2&#xD;
      immunological reaction. In addition, it will also provide first data on the proposed outbreak&#xD;
      response to type 2 (either with mOPV 2 or with a combination of mOPV 2 and IPV 2).&#xD;
&#xD;
      This study will provide data to National Immunization Authorities in order to make strategic&#xD;
      decisions about their polio vaccination schedules in anticipation of the global tOPV to bOPV&#xD;
      switch and will provide data on the proposed responses to type 2 poliovirus outbreaks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in seroprevalence of neutralizing antibodies for type 2 in 19 weeks of age between arms</measure>
    <time_frame>19 weeks of age</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroprevalence of neutralizing antibodies at 18 weeks of age</measure>
    <time_frame>18 weeks of age</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Difference in shedding of poliovirus type 2 in stool in 19 weeks of age between arms</measure>
    <time_frame>19 weeks of age</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Difference in seroprevalence of neutralizing antibodies at 22 weeks of age between arms</measure>
    <time_frame>22 weeks of age</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">900</enrollment>
  <condition>Poliomyelitis</condition>
  <arm_group>
    <arm_group_label>IPV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IPV at birth, 6 weeks, 10 weeks, 14 weeks, followed by tOPV at 18 and 22 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bOPV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bOPV at birth, 6, 10, and 14 weeks. followed by tOPV at 18 and 22 weeks of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bOPV and IPV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bOPV at birth, 6, 10 weeks, and IPV+bOPV at 14 weeks, and tOPV at 18 and 22 weeks of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bOPV and IPV and IPV2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bOPV at birth, 6, 10 weeks and bOPV+IPV at 14 weeks and tOPV+IPV2 at 18 weeks and tOPV alone at 22 weeks of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tOPV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tOPV at birth, 6, 10, 14, 18 and 22 weeks of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IPV</intervention_name>
    <description>IPV at birth, 6, 10, 14 weeks of age and tOPV at 18 and 22 weeks of age</description>
    <arm_group_label>IPV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bOPV</intervention_name>
    <description>bOPV at birth, 6, 10, 14 weeks and tOPV at 18 and 22 weeks of age</description>
    <arm_group_label>bOPV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bOPV and IPV</intervention_name>
    <description>bOPV till week 10, bOPV+IPV at 14 and tOPV at 18 and 22 weeks of age</description>
    <arm_group_label>bOPV and IPV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bOPV and IPV and IPV2</intervention_name>
    <description>bOPV till week 10, bOPV+IPV at 14, tOPV+IPV2 at 18 and tOPV at 22 weeks of age</description>
    <arm_group_label>bOPV and IPV and IPV2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tOPV</intervention_name>
    <description>tOPV till 22 weeks of age</description>
    <arm_group_label>tOPV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newborn of either gender born healthy with birth weight 2.0 kg or more, with immediate&#xD;
             cry, at the study sites (home or health facility births)&#xD;
&#xD;
          -  Not planning to travel away during entire the study period (birth-154 days; birth 22&#xD;
             weeks).&#xD;
&#xD;
          -  Parents resident of the study area for last 3 month at the time of enrolment&#xD;
&#xD;
          -  Parent/guardian provides informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Newborns found acutely ill at the time of enrolment and requiring emergent medical&#xD;
             care/hospitalization, birth weight below 2.0 kg, cry &gt;2 minutes after birth, or family&#xD;
             is planning to be absent during the birth - 154 days study period&#xD;
&#xD;
          -  Refusal of blood testing and cord blood testing&#xD;
&#xD;
          -  Receipt of OPV after birth before eligibility screen&#xD;
&#xD;
          -  Newborns with certain medical conditions i.e., syndromic infants, neonate with&#xD;
             petechial or purpura (contraindication of intramuscular injections)&#xD;
&#xD;
          -  A diagnosis or suspicion of immunodeficiency disorder (either in the participant or in&#xD;
             a member of the immediate family - e.g. several early infant deaths, household member&#xD;
             on chemotherapy) will render the newborn ineligible for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Day</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali F Saleem, MBBS,FCPS,MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aga Khan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rehri goth, Ibrahim Hyderi, Ali Akbar Shah, and Bhens Colony</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>July 9, 2014</study_first_submitted>
  <study_first_submitted_qc>July 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2014</study_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aga Khan University</investigator_affiliation>
    <investigator_full_name>Ali Faisal Saleem</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>IPV</keyword>
  <keyword>OPV</keyword>
  <keyword>tOPV</keyword>
  <keyword>bOPV</keyword>
  <keyword>Polio</keyword>
  <keyword>Endgame</keyword>
  <keyword>Pakistan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

